Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001415889-25-003984
Filing Date
2025-02-14
Accepted
2025-02-14 11:21:13
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 38588
2 JOINT FILING AGREEMENT ex-99-02142025_040216.htm EX-99.1 12301
  Complete submission text file 0001415889-25-003984.txt   52656
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Subject) CIK: 0001563880 (see all company filings)

EIN.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91005 | Film No.: 25625039
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304
Business Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A